Progress from clinical trials and emerging non-conventional therapies for the treatment of Medulloblastomas

Cancer Letters

Volumn 330, Issue 2, 2013, Pages 130-140

  Ajeawung, Norbert Fonya ^a   Wang, Hao Yang ^a   Kamnasaran, Deepak ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Childhood brain tumors; Pediatric cancers; Therapies

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEHYDRODIDEMNIN B; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ETOPOSIDE; FIRTECAN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LATENT MEMBRANE PROTEIN 2; MELPHALAN; MK 0752; NAVELBINE; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; PLERIXAFOR; PROTEIN PATCHED 1; SONIC HEDGEHOG PROTEIN; TEMOZOLOMIDE; THIOTEPA; TIPIFARNIB; UNINDEXED DRUG; VISMODEGIB;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BASAL CELL CARCINOMA; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DNA DAMAGE; DRUG BINDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG TOXICITY; DYSGEUSIA; ERYTHEMA; ESTERIFICATION; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENE MUTATION; HUMAN; INFECTION; INTENSITY MODULATE PROTON THERAPY; IONIZING RADIATION; LEUKEMIA; LOW DRUG DOSE; LUNG DISEASE; LYMPHOCYTOPENIA; MEDULLOBLASTOMA; MELANOMA; MICROTUBULE; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; NAUSEA; NERVOUS SYSTEM TUMOR; NEUROBLASTOMA; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONCONVENTIONAL CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON RADIATION; PROTON THERAPY; PTCH1 GENE; RECURRENT CANCER; RHABDOMYOSARCOMA; SALVAGE THERAPY; SAMPLE SIZE; SEPSIS; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME; TUMOR CELL LINE; VOMITING; WEIGHT REDUCTION;

ERINACEIDAE;

EID: 84873099101     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.039     Document Type: Review

References (111)

1. Gajjar A., Chintagumpala M., Ashley D., Kellie S., Kun L.E., Merchant T.E., Woo S., Wheeler G., Ahern V., Krasin M.J., Fouladi M., Broniscer A., Krance R., Hale G.A., Stewart C.F., Dauser R., Sanford R.A., Fuller C., Lau C., Boyett J.M., Wallace D., Gilbertson R.J. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. The Lancet Oncology 2006, 7:813-820.
2. Ellison D., Dalton J., Kocak M., Nicholson S., Fraga C., Neale G., Kenney A., Brat D., Perry A., Yong W., Taylor R., Bailey S., Clifford S., Gilbertson R. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica 2011, 121:381-396.
3. von Hoff K., Hartmann W., von Bueren A.O., Gerber N.U., Grotzer M.A., Pietsch T., Rutkowski S. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatric Blood and Cancer 2010, 54:369-376.
4. Giangaspero F., Rigobello L., Badiali M., Loda M., Andreini L., Basso G., Zorzi F., Montaldi A. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior, American Journal of Surgical Pathology 1992, 16:687-693.
5. Rutkowski S., von Hoff K., Emser A., Zwiener I., Pietsch T., Figarella-Branger D., Giangaspero F., Ellison D.W., Garre M.-L., Biassoni V., Grundy R.G., Finlay J.L., Dhall G., Raquin M.-A., Grill J. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. Journal of Clinical Oncology 2010, 28:4961-4968.
6. Ajeawung N.F., Wang H., Gould P., Kamnasaran D. Advances in molecular targets for the treatment of Medulloblastomas. Clinical Investigation Medicine 2012, 35(5):E246.
7. Northcott P.A., Korshunov A., Pfister S.M., Taylor M.D. The clinical implications of medulloblastoma subgroups. Nature Review Neurology 2012, 8:340-351.
8. Drabløs F., Feyzi E., Aas P.A., Vaagbø C.B., Kavli B., Bratlie M.S., Peña-Diaz J., Otterlei M., Slupphaug G., Krokan H.E. Alkylation damage in DNA and RNA - repair mechanisms and medical significance. DNA Repair (Amst) 2004, 3:1389-1407.
9. Barone G., Maurizi P., Tamburrini G., Riccardi R. Role of temozolomide in pediatric brain tumors. Childs Nervous System 2006, 22.
10. Hongeng S., Visudtibhan A., Dhanachai M., Laothamatus J., Chiamchanya S. Treatment of leptomeningeal relapse of medulloblastoma with temozolomide. Journal of Pediatric Hematology/Oncology 2002, 24:591-593.
11. Baruchel S., Diezi M., Hargrave D., Stempak D., Gammon J., Moghrabi A., Coppes M.J., Fernandez C.V., Bouffet E. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. European Journal of Cancer 2006, 42:2335-2342.
12. Padovani L., Andre N., Gentet J.C., Figarella Branger D., Scavarda D., Verschuur A., Chinot O., Cowen D., Muracciole X. Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?. Journal of Pediatric Hematology/Oncology 2011, 33:600-604. 610.1097/MPH.1090b1013e3182331eaf.
13. Nicholson H.S., Kretschmar C.S., Krailo M., Bernstein M., Kadota R., Fort D., Friedman H., Harris M.B., Tedeschi-Blok N., Mazewski C., Sato J., Reaman G.H. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors. Cancer 2007, 110:1542-1550.
14. Ruggiero A., Rizzo D., Attinà G., Lazzareschi I., Mastrangelo S., Maurizi P., Migliorati R., Bertolini P., Pastore M., Colosimo C., Riccardi R. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma. European Journal of Cancer 2010, 46:2943-2949.
15. Fouladi M., Gururangan S., Moghrabi A., Phillips P., Gronewold L., Wallace D., Sanford R.A., Gajjar A., Kun L.E., Heideman R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 2009, 115:3243-3253.
16. Heideman R.L., Kovnar E.H., Kellie S.J., Douglass E.C., Gajjar A.J., Walter A.W., Langston J.A., Jenkins J.J., Li Y., Greenwald C. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. Journal of Clinical Oncology 1995, 13:2247-2254.
17. Gentet J.C., Doz F., Bouffet E., Plantaz D., Roche H., Tron P., Kalifa C., Mazingue F., Sariban E., Chastagner P., et al. Carboplatin and VP 16 in medulloblastoma: a phase II study of the french society of pediatric oncology (SFOP). Medical and pediatric oncology 1994, 23:422-427.
18. Kellie S.J., Wong C.K.F., Pozza L.D., Waters K.D., Lockwood L., Mauger D.C., White L. Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children. Medical and Pediatric Oncology 2002, 39:168-174.
19. Wedge S.R., Porteus J.K., May B.L., Newlands E.S. Potentization of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. British Journal of Cancer 1996, 73:482-490.
20. Middlemas D.S., Stewart C.F., Kirstein M.N., Poquette C., Friedman H.S., Houghton P.J., Brent T.P. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clinical Cancer Research 2000, 6:998-1007.
21. Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., Bouffet E., Clifford S.C., Hawkins C.E., French P., Rutka J.T., Pfister S., Taylor M.D. Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 11:1408.
22. Guha M. Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential. Nature Review Drug Discovery 2012, 11:257-258.
23. LoRusso P.M., Rudin C.M., Reddy J.C., Tibes R., Weiss G.J., Borad M.J., Hann C.L., Brahmer J.R., Chang I., Darbonne W.C., Graham R.A., Zerivitz K.L., Low J.A., Von Hoff D.D. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory. Locally Advanced or Metastatic Solid Tumors, Clinical Cancer Research 2011, 17:2502-2511.
24. Metcalfe C., de Sauvage F.J. Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists. Cancer Research 2011, 71:5057-5061.
25. Shih I.-M., Wang T.-L. Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Research 2007, 67:1879-1882.
26. Fouladi M., Stewart C.F., Olson J., Wagner L.M., Onar-Thomas A., Kocak M., Packer R.J., Goldman S., Gururangan S., Gajjar A., Demuth T., Kun L.E., Boyett J.M., Gilbertson R.J. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Clinical Oncology 2011, 29:3529-3534.
27. Krop I., Demuth T., Guthrie T., Wen P.Y., Mason W.P., Chinnaiyan P., Butowski N., Groves M.D., Kesari S., Freedman S.J., Blackman S., Watters J., Loboda A., Podtelezhnikov A., Lunceford J., Chen C., Giannotti M., Hing J., Beckman R., LoRusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (notch) inhibitor MK-0752 in adult patients with advanced solid tumors. Journal of Clinical Oncology 2012, 30:2307-2313.
28. Broggini M., Marchini S.V., Galliera E., Borsotti P., Taraboletti G., Erba E., Sironi M., Jimeno J., Faircloth G.T., Giavazzi R., Dincalci M. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003, 17:52-59.
29. Straight A.M., Oakley K., Moores R., Bauer A.J., Patel A., Tuttle R.M., Jimeno J., Francis G.L. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemotherapy and Pharmacology 2006, 57:7-14.
30. Biscardi M., Caporale R., Balestri F., Gavazzi S., Jimeno J., Grossi A. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Annals of Oncology 2005, 16:1667-1674.
31. García-Fernández L.F., Losada A., Alcaide V., Alvarez A.M., Cuadrado A., González L., Nakayama K., Nakayama K.I., Fernández-Sousa J.M., Muñoz A., Sánchez-Puelles J.M. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002, 21:7533-7544.
32. 2-terminal kinase activation in human melanoma cells. Journal of Pharmacology and Experimental Therapeutics 2008, 324:1093-1101.
33. Cuadrado A., Garci{dotless}́a-Fernández L.F., González L., Suárez Y., Losada A., Alcaide V., Marti{dotless}́nez T., Fernández-Sousa J.a., Sánchez-Puelles J.M.a., Muñoz A. Aplidin™ Induces Apoptosis in Human Cancer Cells via Glutathione Depletion and Sustained Activation of the Epidermal Growth Factor Receptor, Src, JNK, and p38 MAPK. Journal of Biological Chemistry 2003, 278:241-250.
34. Geoerger B., Estlin E.J., Aerts I., Kearns P., Gibson B., Corradini N., Doz F., Lardelli P., Miguel B.D., Soto A., Prados R., Vassal G. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an innovative therapies for children with cancer (ITCC) study. European Journal of Cancer 2012, 48:289-296.
35. Baldwin E.L., Osheroff N. Etoposide. Topoisomerase II and Cancer, Current Medicinal Chemistry - Anti-Cancer Agents 2005, 5:363-372.
36. Vos S.M., Tretter E.M., Schmidt B.H., Berger J.M. All tangled up: how cells direct, manage and exploit topoisomerase function. Nature Reviews Molecular Cell Biology 2011, 12:827-841.
37. Chamberlain M.C., Kormanik P.A. Chronic oral VP-16 for recurrent medulloblastoma. Pediatric Neurology 1997, 17:230-234.
38. Needle M.N., Molloy P.T., Geyer J.R., Herman-Liu A., Belasco J.B., Goldwein J.W., Sutton L., Phillips P.C. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Medical and Pediatric Oncology 1997, 29:28-32.
39. Silvani A., Gaviani P., Lamperti E., Botturi A., DiMeco F., Franzini A., Ferroli P., Fariselli L., Milanesi I., Erbetta A., Pollo B., Salmaggi A. Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. Journal of Neuro-Oncology 2012, 106:595-600.
40. Vassal G., Pondarre C., Boland I., Cappelli C., Santos A., Thomas C., Lucchi E., Imadalou K., Pein F., Morizet J., Gouyette A. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 1998, 80:271-280.
41. Vassal G., Doz F., Frappaz D., Imadalou K., Sicard E., Santos A., O'Quigley J., Germa C., Risse M.-L., Mignard D., Pein F. A Phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. Journal of Clinical Oncology 2003, 21:3844-3852.
42. Turner C.D., Gururangan S., Eastwood J., Bottom K., Watral M., Beason R., McLendon R.E., Friedman A.H., Tourt-Uhlig S., Miller L.L., Friedman H.S. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-Oncology 2002, 4:102-108.
43. A.S. Levy, P.A. Meyers, L.H. Wexler, R. Jakacki, A. Angiolillo, S.N. Ringuette, M.B. Cohen, R. Gorlick, M.D. Other site principal investigators: Wayne Furman, M.D. Rochelle Bagatell, M.D. Lori Luchtman-Jones, M.D. Luis Eduardo Garcia, M.D. Eric Sandler, Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1-21 years with refractory solid tumors, Cancer 115 (2009) 207-216.
44. Hurwitz C.A., Strauss L.C., Kepner J., Kretschmar C., Harris M.B., Friedman H., Kun L., Kadota R. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology Phase II study. Journal of Pediatric Hematology/Oncology 2001, 23:277-281.
45. Zwerdling T., Krailo M., Monteleone P., Byrd R., Sato J., Dunaway R., Seibel N., Chen Z., Strain J., Reaman G. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors. Cancer 2006, 106:1821-1828.
46. Minard-Colin V., Ichante J.-L., Nguyen L., Paci A., Orbach D., Bergeron C., Defachelles A.-S., André N., Corradini N., Schmitt C., Tabone M.-D., Blouin P., Sirvent N., Goma G., Geoerger B., Oberlin O. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). European Journal of Cancer (Oxford, England : 1990) 2012.
47. Horwitz S.B. Taxol (paclitaxel): mechanisms of action. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 1994, 5(Suppl 6):S3-S6.
48. Sinclair W.K. Cyclic X-ray responses in mammalian cells in vitro. Radiation Research 1968, 33:620-643.
49. Gannett D.E., Hill D., Hamilton A.J., Stea B. Paclitaxel as a radiosensitizer combined with fractionated stereotactic radiotherapy in the treatment of recurrent medulloblastoma. American Journal of Clinical Oncology 1997, 20:233-236.
50. Kuttesch J.F., Krailo M.D., Madden T., Johansen M., Bleyer A. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a children's oncology group study. Pediatric Blood and Cancer 2009, 53:590-593.
51. Geoerger B., Chisholm J., Le Deley M.-C., Gentet J.-C., Zwaan C.M., Dias N., Jaspan T., Mc Hugh K., Couanet D., Hain S., Devos A., Riccardi R., Cesare C., Boos J., Frappaz D., Leblond P., Aerts I., Vassal G. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with cancer european consortium study. European Journal of Cancer (Oxford, England: 1990) 2011, 47:230-238.
52. Fouladi M., Nicholson H.S., Zhou T., Laningham F., Helton K.J., Holmes E., Cohen K., Speights R.A., Wright J., Pollack I.F. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a children's oncology group study. Cancer 2007, 110:2535-2541.
53. Bomgaars L.R., Bernstein M., Krailo M., Kadota R., Das S., Chen Z., Adamson P.C., Blaney S.M. Phase II trial of irinotecan in children with refractory solid tumors: a children's oncology group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007, 25:4622-4627.
54. Mimeault M., Batra S. Great Promise of Tissue-Resident Adult Stem/Progenitor Cells in Transplantation and Cancer Therapies Stem Cell Transplantation 2012, 171-186. Springer, US. C. López-Larrea, A. López-Vázquez, B. Suárez-álvarez (Eds.).
55. Aabideen K., Anoop P., Ethell M.E., Potter M.N. The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. Journal of Pediatric Hematology/Oncology 2011, 33:65-67.
56. Cardenoux C., Oudot C., Deméocq F., Roussanne M.-C., Piguet C., Kanold J., Merlin E. Pegfilgrastim plus AMD 3100 for stem-cell mobilization in children. Pediatric Blood and Cancer 2010, 55:769.
57. Dupuis-Girod S., Hartmann O., Benhamou E., Doz F., Mechinaud F., Bouffet E., Coze C., Kalifa C. High-dose chemotherapy in relapse of medulloblastoma in young children. Bull Cancer 1997, 84:264-272.
58. Mahoney D.H., Strother D., Camitta B., Bowen T., Ghim T., Pick T., Wall D., Yu L., Shuster J.J., Friedman H. High-dose Melphalan and Cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. Journal of Clinical Oncology 1996, 14:382-388.
59. Dunkel I.J., Boyett J.M., Yates A., Rosenblum M., Garvin J.H., Bostrom B.C., Goldman S., Sender L.S., Gardner S.L., Li H., Allen J.C., Finlay J.L. High-dose Carboplatin, Thiotepa, and Etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group, Journal of Clinical Oncology 1998, 16:222-228.
60. Dunkel I.J., Gardner S.L., Garvin J.H., Goldman S., Shi W., Finlay J.L. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro-Oncology 2010, 12:297-303.
61. Park J.E., Kang J., Yoo K.H., Sung K.W., Koo H.H., Lim D.H., Shin H.J., Kang H.J., Park K.D., Shin H.Y., Kim I.H., Cho B.-K., Im H.J., Seo J.J., Park H.J., Park B.-K., Ahn H.S. Efficacy of High-dose chemotherapy and autologous stem cell transplantation in patients with relapsed medulloblastoma: a report on The Korean Society for Pediatric Neuro-Oncology (KSPNO)-S-053 study. Journal of Korean Medical Science 2010, 25:1160-1166.
62. Laurent J.P., Chang C.H., Cohen M.E. A classification system for primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Cancer 1985, 56:1807-1809.
63. Pérez-Martínez A., Lassaletta A., González-Vicent M., Sevilla J., Díaz M.A., Madero L. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of Neuro-Oncology 2005, 71:33-38.
64. Gururangan S., Krauser J., Watral M., Driscoll T., Larrier N., Reardon D., Rich J., Quinn J., Vredenburgh J., Desjardins A., McLendon R., Fuchs H., Kurtzberg J., Friedman H.S. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology 2008, 10:745-751.
65. Butturini A., Jacob M., Aguajo J., Vander-Walde N., Villablanca J., Jubran R., Erdreich-Epstein A., Marachelian A., Dhall G., Finlay J. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Cancer 2009, 115:2956-2963.
66. Sung K.W., Yoo K.H., Cho E.J., Koo H.H., Lim do H., Shin H.J., Ahn S.D., Ra Y.S., Choi E.S., Ghim T.T. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatric Blood and Cancer 2007, 48:408-415.
67. Dupuis-Girod S., Hartmann O., Benhamou E., Doz F., Mechinaud F., Bouffet E., Coze C., Kalifa C. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?. Journal of Neuro-Oncology 1996, 27:87-98.
68. Zia M., Forsyth P., Chaudhry A., Russell J., Stewart D. Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma. Bone Marrow Transplantation 2002, 30:565-569.
69. Valteau-Couanet D., Fillipini B., Benhamou E., Grill J., Kalifa C., Couanet D., Habrand J.L., Hartmann O. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplantation 2005, 36:939-945.
70. Aihara Y., Tsuruta T., Kawamata T., Kanno H., Maebayashi K., Sakauchi M., Wada E., Osawa M., Fujii H., Kubo O., Hori T. Double high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation for primary disseminated medulloblastoma: a report of 3 cases. Journal of Pediatric Hematology/Oncology 2010, 32:e70-e74. (10).
71. Ridola V., Grill J., Doz F., Gentet J.-C., Frappaz D., Raquin M.-A., Habrand J.-L., Sainte-Rose C., Valteau-Couanet D., Kalifa C. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007, 110:156-163.
72. Gerosa M., Amadori G., Semenzato C., Raumer R., Cisotto P., Pezzuto A., Gasparotto G., Carteri A. Immunobiology of paediatric intracranial tumours, a preliminary report. Acta Neurochir (Wien) 1979, 50:49-54.
73. Gerosa M., Amadori G., Semenzato P., Gasparotto G., Carteri A. Immunobiology of primary CNS tumors in infancy and childhood, B- and T-cell dependent immunity and cytotoxicity and cell kinetic evaluation. Childs Brain 1980, 6:92-102.
74. Raffaghello L., Nozza P., Morandi F., Camoriano M., Wang X., Garrè M.L., Cama A., Basso G., Ferrone S., Gambini C., Pistoia V. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Research 2007, 67:5471-5478.
75. Trinchieri G. Biology of natural killer cells. Advances in Immunology 1989, 47:187-376.
76. Castriconi R., Dondero A., Negri F., Bellora F., Nozza P., Carnemolla B., Raso A., Moretta L., Moretta A., Bottino C. Both CD133 and CD133 - Medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK - Mediated cytotoxicity. European Journal of Immunology 2007, 37:3190-3196.
77. Kang S., Ryu C., Jeun S., Park C., Shin H., Kim J., Kim M., Kang J. Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood. Child's Nervous System 2004, 20:154-162.
78. Okamoto Y., Shimizu K., Tamura K., Miyao Y., Yamada M., Matsui Y., Tsuda N., Takimoto H., Hayakawa T., Mogami H. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 1988, 94:47-52.
79. George R.E., Loudon W.G., Moser R.P., Bruner J.M., Steck P.A., Grimm E.A. In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. Journal of Neurosurgery 1988, 69:403-409.
80. Oba-Shinjo S.M., Caballero O.L., Jungbluth A.A., Rosemberg S., Old L.J., Simpson A.J., Marie S.K. Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immunity 2008, 8:7.
81. Boon T., Coulie P.G., Eynde B.J.V.d., Bruggen P.v.d. Human T cell responses against melanoma. Annual Review of Immunology 2006, 24:175-208.
82. Toh H.C., Wang W.-W., Chia W.K., Kvistborg P., Sun L., Teo K., Phoon Y.P., Soe Y., Tan S.H., Hee S.W., Foo K.F., Ong S., Koo W.H., Zocca M.-B., Claesson M.H. Clinical benefit of allogeneic melanoma cell lysate - pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clinical Cancer Research 2009, 15:7726-7736.
83. Kim S.H., Castro F., Gonzalez D., Maciag P.C., Paterson Y., Gravekamp C. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. British Journal of Cancer 2008, 99:741-749.
84. Dachs G.U., Hunt M.A., Syddall S., Singleton D.C., Patterson A.V. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009, 14:4517-4545.
85. Kim S.U. Neural stem cell-based gene therapy for brain tumors. Stem Cell Review 2011, 7:130-140.
86. Rosolen A., Frascella E., di Francesco C., Todesco A., Petrone M., Mehtali M., Zacchello F., Zanesco L., Scarpa M. In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Therapy 1998, 5:113-120.
87. Pu K., Li S.-y., Gao Y., Ma L., Ma W., Liu Y. Bystander effect in suicide gene therapy using immortalized neural stem cells transduced with herpes simplex virus thymidine kinase gene on medulloblastoma regression. Brain Research 2011, 1369:245-252.
88. Wang H.W., Breslin M.B., Chen C., Akerstrom V., Zhong Q., Lan M.S. INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors. Human Gene Therapy 2009, 20:1308-1318.
89. DeSmaele E., Fragomeli C., Ferretti E., Pelloni M., Po A., Canettieri G., Coni S., Dimarcotullio L., Greco A., Moretti M., Dirocco C., Pazzaglia S., Maroder M., Screpanti I., Giannini G., Gulino A. An integrated approach identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated genes in developing cerebellum and medulloblastoma. Neoplasia 2008, 10:89-98.
90. Lim S.H., Choi S.A., Lee J.Y., Wang K.C., Phi J.H., Lee D.H., Song S.H., Song J.H., Jin X., Kim H., Lee H.J., Lim I., Kim S.U., Kim S.K. Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase. Cancer Gene Therapy 2011, 18:817-824.
91. Gutova M., Shackleford G.M., Khankaldyyan V., Herrmann K.A., Shi X.H., Mittelholtz K., Abramyants Y., Blanchard M.S., Kim S.U., Annala A.J., Najbauer J., Synold T.W., D'Apuzzo M., Barish M.E., Moats R.A., Aboody K.S. Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma. Gene Therapy 2012.
92. Kooy H.M., Dunbar S.F., Tarbell N.J., Mannarino E., Ferarro N., Shusterman S., Bellerive M., Finn L., McDonough C.V., Loeffler J.S. Adaptation of the relocatable Gill-Thomas-Cosman frame in stereotactic radiotherapy. International Journal of Radiation Oncology, Biology, Physics 1994, 30:685-691.
93. Packer R.J., Cogen P., Vezina G., Rorke L.B. Medulloblastoma: clinical and biologic aspects. Neuro-Oncology 1999, 1:232-250.
94. Smitt M.C., McPeak E.M., Donaldson S.S. The advantages of three dimensional conformal radiotherapy of childhood cancer. Radiation Research 1998, 150:S170-S177.
95. E. Huang, B.S. Teh, D.R. Strother, Q.G. Davis, J.K. Chiu, H.H. Lu, L.S. Carpenter, W.Y. Mai, M.M. Chintagumpala, M. South, W.H. 3rd Grant, E.B. Butler, S.Y. Woo, Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction in ototoxicity, International Journal of Radiation Oncology, Biology, Physics 52 (2002) 599-605.
96. Stavrou T., Bromley C.M., Nicholson H.S., Byrne J., Packer R.J., Goldstein A.M., Reaman G.H. Prognostic factors and secondary malignancies in childhood medulloblastoma. Journal of Pediatric Hematology/Oncology 2001, 23:431-436.
97. Moppett J., Oakhill A., Duncan A.W. Second malignancies in children: the usual suspects?. European Journal of Radiology 2001, 38:235-248.
98. Newhauser W.D., Fontenot J.D., Mahajan A., Kornguth D., Stovall M., Zheng Y., Taddei P.J., Mirkovic D., Mohan R., Cox J.D., Woo S. The risk of developing a second cancer after receiving craniospinal proton irradiation. Physics in Medicine and Biology 2009, 54:2277-2291.
99. Lee C.T., Bilton S.D., Famiglietti R.M., Riley B.A., Mahajan A., Chang E.L., Maor M.H., Woo S.Y., Cox J.D., Smith A.R. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?. International Journal of Radiation Oncology, Biology, Physics 2005, 63:362-372.
100. St Clair W.H., Adams J.A., Bues M., Fullerton B.C., La Shell S., Kooy H.M., Loeffler J.S., Tarbell N.J. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. International Journal of Radiation Oncology, Biology, Physics 2004, 58:727-734.
101. Miralbell R., Lomax A., Russo M. Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation. International Journal of Radiation Oncology, Biology, Physics 1997, 38:805-811.
102. MacDonald S.M., Safai S., Trofimov A., Wolfgang J., Fullerton B., Yeap B.Y., Bortfeld T., Tarbell N.J., Yock T. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. International Journal of Radiation Oncology, Biology, Physics 2008, 71:979-986.
103. Steneker M., Lomax A., Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2006, 80:263-267.
104. Taheri-Kadkhoda Z., Björk-Eriksson T., Nill S., Wilkens J.J., Oelfke U., Johansson K.A., Huber P.E., Münter M.W. Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2008, 3:4.
105. Yuh G.E., Loredo L.N., Yonemoto L.T., Bush D.A., Shahnazi K., Preston W., Slater J.M., Slater J.D. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. The Cancer Journal 2004, 10:386-390.
106. Chung C.S., Keating N., Yock T., Tarbell N. Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy. International Journal of Radiation Oncology, Biology, Physics 2008, 72:S8.
107. Howell R.M., Giebeler A., Koontz-Raisig W., Mahajan A., Etzel C.J., D'Amelio A.M., Homann K.L., Newhauser W.D. Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2012, 7:116.
108. Miralbell R., Lomax A., Cella L., Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. International Journal of Radiation Oncology, Biology, Physics 2002, 54:824-829.
109. P Brodin N., Munck Af Rosenschöld P., Aznar M.C., Kiil-Berthelsen A., Vogelius I.R., Nilsson P., Lannering B., Björk-Eriksson T. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncologica 2011, 50:806-816.
110. Blomstrand M., Brodin N.P., Munck Af Rosenschöld P., Vogelius I.R., Sánchez Merino G., Kiil-Berthlesen A., Blomgren K., Lannering B., Bentzen S.M., Björk-Eriksson T. Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro-Oncology 2012, 14:882-889.
111. Lundkvist J., Ekman M., Ericsson S.R., Jönsson B., Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer 2005, 103:793-801.